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ABSTRACT
COntext and ObjeCtive: Gene expression and immunohistochemical profiling of diffuse large B-cell lymphoma (DLBCL) have revealed important 
prognostic subgroups: germinal center B-cell-like (GCB-like) DLBCL and activated B cell-like (ABC-like) DLBCL. Although few reports on high-risk DLBCL 
are available, the prognosis for the GCB-like subgroup has been shown to be better than that of the ABC-like subgroup. The role of Bcl-2 as a predictor of 
survival in DLBCL cases is unclear and its expression varies between the two subgroups of DLBCL. In this study, we analyzed the frequency and prognostic 
impact of Bcl-2 protein expression in high-risk DLBCL cases.  
deSiGn and SettinG: Retrospective cohort study among DLBCL patients treated at Hospital das Clínicas, Faculdade de Medicina da Universidade de 
São Paulo (HC-FMUSP). 
MethOdS: The prognostic impact of the expression of the proteins CD10, Bcl-6, MUM1 (multiple myeloma oncogene-1) and Bcl-2 on high-risk DLBCL 
cases was evaluated by means of immunohistochemistry. Seventy-three patients aged 18-60 years were evaluated for all these markers. 
ReSultS: Twenty-four cases (32.9%) were GCB-like and 49 (67.1%) were ABC-like, with no difference regarding complete remission, disease-free survival 
or overall survival rates. Twenty-seven patients (37%) showed Bcl-2 expression, which was the only independent factor predicting a worse prognosis for 
overall survival according to multivariate analysis. 
COnCluSiOn: Bcl-2 protein was expressed in 37% of the high-risk DLBCL patients, without any difference between the ABC-like DLBCL and GCB-like 
DLBCL cases. 
RESUMO
COntextO e ObjetivO: A expressão gênica e imunoistoquímica do linfoma difuso de grandes células B (LDGCB) vem permitindo a identificação de 
importantes subgrupos prognósticos: LDGCB do centro germinativo (CG) e LDGCB de células B ativadas (CBA). Entretanto, existem poucos dados 
disponíveis com LDGCB de alto risco, sendo o prognóstico dos LDGCB do CG melhor que os LDGCB de CBA. A participação do Bcl-2 como preditor de 
sobrevida nos LDGCB não é clara e sua expressão é variável entre os dois subgrupos de LDGCB. Neste estudo é avaliada a frequência e o prognóstico 
da expressão da proteína Bcl-2 em LDGCB de alto risco. 
tipO de eStudO e lOCal: Estudo de coorte retrospectivo realizado entre portadores de LDGCB tratados no Hospital das Clínicas da Faculdade de 
Medicina da Universidade de São Paulo. 
MétOdOS: Foi avaliado o impacto prognóstico da expressão das proteínas CD10, Bcl-6, MUM1 (multiple myeloma oncogene-1) e Bcl-2 por 
imunoistoquímica em LDGCB de alto risco. Foram avaliados, para todos os marcadores, 73 pacientes com idade de 18 a 60 anos. 
ReSultadOS: Vinte e quatro (32,9%) pacientes foram classificados como LDGCB do CG e 49 (67,1%) como LDGCB de CBA, sem diferença nas taxas de 
remissão completa, sobrevida livre de doença e sobrevida global. Vinte e sete (37%) apresentaram expressão de Bcl-2, o qual foi o único fator preditivo 
independente de pior prognóstico de sobrevida global à análise multivariada.
COnCluSãO: A expressão da proteína Bcl-2 ocorreu em 37% dos portadores de LDGCB de alto risco, sem diferença entre os subgrupos de LDGCB do 
CG ou de CBA.
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InTROdUCTIOn
Diffuse large B-cell lymphoma (DLBCL) is a clinically and biologi-
cally heterogeneous disease that accounts for 30-35% of non-Hodgkin 
lymphoma (NHL) cases. About 58% of these cases are of high-inter-
mediate or high international prognostic index (IPI) risk and 30-50% 
are cured with conventional cyclophosphamide, doxorubicin, vincris-
tine and prednisone-like (CHOP-like) regimens.1,2 The gene expres-
sion shown by deoxyribonucleic acid (DNA) microarrays and by im-
munohistochemical staining has revealed different DLBCL prognostic 
subgroups according to the gene expression of malignant cells.3-5 Better 
prognosis has been demonstrated for germinal center B-cell-like (GCB-
like) DLBCL cases than for activated B cell-like (ABC-like) DLBCL 
cases, regardless of IPI.6 However, most of these studies have includ-
ed patients from different risk groups, whereas it is possible that most 
ABC-like DLBCL cases are from high-risk groups.7 Moreover, the prog-
nosis for DLBCL cases presenting Bcl-2 expression remains unclear, and 
there are few studies on this protein in high IPI risk groups alone.8,9
OBJECTIVE
To analyze the frequency and evolution of Bcl-2 expression in high-
risk DLBCL patients according to the two subgroups.  
METhOdS
Patients and treatment
After obtaining approval from the Ethics Committee, a retrospec-
tive study was conducted. Between January 1992 and December 2005, 
73 patients aged 18-60 years with high-intermediate or high risk DL-
BCL according to the aaIPI (age adjusted international prognostic 
index)1,2 were treated with CHOP or a CHOP-like protocol. Fourteen 
cases (19.1%) were consolidated with autologous bone marrow trans-
plantation (ABMT) during the first complete remission. Patients who 
were human immunodeficiency virus (HIV) seropositive or who pre-
sented congestive heart failure, kidney failure or liver failure were not 
included in this study. Radiotherapy at a dose of 30 Gy was given to 
patients with bulky disease (i.e. > 10 cm) 28 days after the last chemo-
therapy or ABMT. Intrathecal chemotherapy (methotrexate 12 mg and 
dexamethasone 2 mg) was administered to patients with testicular dis-
ease or involvement of the facial bones. Refractory or relapsed disease 
was treated using the IVAC (ifosfamide, etoposide, high-dose cytarabi-
ne) protocol as salvage therapy.10 
histology and immunohistochemical staining 
All biopsies were reviewed by a hematopathologist at the Depart-
ment of Pathological Anatomy of Hospital das Clínicas, Faculdade de 
Medicina da Universidade de São Paulo (HC-FMUSP). The GCB-like 
antigens Bcl-6 and CD10 and the ABC-like antigen MUM1 (multi-
ple myeloma oncogene-1) were investigated by means of immunohis-
tochemical reactions in  order to define whether GCB-like DLBCL or 
ABC-like DLBCL was present.11 All the patients were also investigat-
ed regarding Bcl-2 antigens, by means of immunohistochemistry. We 
used mouse monoclonal antibodies against Bcl-6 (PIF6, dilution 1:40; 
Novocastra, Newcastle, United Kingdom), MUM1 (MUMIP, dilution 
1:500; Dako, Glostrup, Denmark), CD10 (56C6, dilution 1:250; No-
vocastra, Newcastle, United Kingdom) and Bcl-2 (124, dilution 1:200; 
Dako, Glostrup, Denmark) as recommended by Hsu et al.12 Immuno-
reactivity of neoplastic cells greater than 10% was defined as positive 
for all markers.
Response evaluation
All the patients underwent clinical and laboratory tests such as bi-
lateral bone marrow biopsy and computed tomography of the neck, 
chest, abdomen and pelvis at diagnosis. The scans were repeated after 
the fourth chemotherapy cycle, at the end of the treatment and every 
three months for two years, and then every six months for a further 
three years. In cases of bone marrow disease at diagnosis, the bone mar-
row biopsy was repeated at the end of the treatment. We used Cheson’s 
criteria for response evaluations.13
Statistical analysis
Overall survival was calculated as the time interval between the 
date when the treatment began and either death or the last follow-up. 
Disease-free survival was defined as the time interval between complete 
remission and either first progression, relapse or death. For univariate 
analyses, the chi-square and Fisher exact tests were used to analyze the 
association between Bcl-2 and the categorical variables. The times until 
event endpoints were estimated in accordance with the Kaplan-Meier 
method. Cox’s proportional hazards regression was used for multivari-
ate analyses on overall survival and disease-free survival, using the vari-
ables that presented P values less than 0.05 from univariate analysis. 
The Statistical Package for the Social Sciences (SPSS) 13.0 software was 
used for statistical calculations, and P values less than 0.05 were consid-
ered statistically significant.
RESUlTS
Clinical and immunohistochemical features
Table 1 shows the clinical characteristics of the 73 patients assessed 
by means of immunohistochemistry. Twenty-four (32.9%) of them pre-
sented GCB-like DLBCL and 49 (61.7%) ABC-like DLBCL, with 
similar distributions of clinical features in the two subgroups. Table 2 
shows the patterns of CD10, Bcl-6, MUM1 and Bcl-2 antigen expres-
sion. There was no correlation between Bcl-2 expression and subgroups 
of GCB-like DLBCL and ABC-like DLBCL.
Survival
For the full cohort of patients, the overall survival at 60 months was 
42.8% (confidence interval, CI: 56-93) and the disease-free survival was 
56.7% (CI: 63-110). However, the overall survival went down to 33.7% 
(CI: 35-83) for patients with bulky disease and went up to 53.4% (CI: 
63-114) for patients without bulky disease (P = 0.03). Patients who 
achieved complete remission showed higher overall survival rates than 
did those who did not achieve complete remission with first-line thera-
py (P < 0.0001). Similarly, the disease-free survival (P = 0.015) among 
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GCB-like = germinal center B cell-like; DLBCL = diffuse large B-cell lymphoma; ABC-like = activated B cell-like; 
MUM1 = multiple myeloma oncogene-1. *P < 0.05 (chi-square test).
Table 2. Immunohistochemical staining results
GCb-like dlbCl abC-like dlbCl total
p*
n % n % n %
CD10 14 58.3 0 0 14 19.2 -
Bcl-6 20 83.3 16 32.6 36 49.3 -
MUM1 6 25 33 67.3 39 53.4 -
Bcl-2 9 37.5 18 36.7 27 37 0.574
total 24 32.8 49 67.1 73 89 -
Complete remission Overall survival disease-free survival
% p % p % p
CD10 + 57.4 0.369 49 0.646 54.8 0.342
CD10 - 66.1 - 38.8 - 70 -
Bcl-6 + 49.3 0.128 43.1 0.85 60.5 0.816
Bcl-6 - 56.7 - 45.5 - 54.3 -
MUM1 + 64.1 0.576 46.8 0.95 58.4 0.795
MUM1 - 64.7 - 35.9 - 56.7 -
Bcl-2 + 51.8 0.073 16.4 0.004 34 0.12
Bcl-2 - 72 - 58.1 - 65.6 -
GCB 70.8 0.29 46.8 0.885 60.8 0.365
ABC 61.2 - 43.3 - 55.3 -
Table 3. Outcome according to immunohistochemical staining
MUM1 = multiple myeloma oncogene-1; GCB = germinal center B cell-like; ABC = activated B cell-like.
GCb-like dlbCl abC-like dlbCl total
p*
n % n % n %
Age (years)
Mean ± SD
42.21 ± 
12.52
- 37.33 ± 
12.66
- 0.718
Gender F 10 41.7 21 42.9 31 42.5 0.563
M 14 58.3 28 57.1 42 57.7 -
B symptoms 21 87.5 42 85.7 63 86.3 0.573
Extranodal 7 29.2 25 51 32 43.8 0.064
BM positive 4 16.7 12 24.5 16 21.9 0.33
Bulky 12 50 24 49 36 49.3 0.556
High LDH 22 91.7 44 89.8 66 90.4 0.582
Stage I/II
III/IV
5 20.8 10 20.4 15 20.5 0.597
19 79.2 39 79.6 58 79.5 -
aaIPI H-I 17 70.8 30 61.2 47 64.4 0.295
High 7 29.2 19 38.8 26 35.6 -
total 24 100 49 100 73 100 -
Table 1. Clinical data on the 73 patients evaluated
GCB-like = germinal center B cell-like; DLBCL = diffuse large B-cell lymphoma; ABC-like = activated B cell-like; 
SD = standard deviation; F = female; M = male; B symptoms: recurrent fever (temperature, >38.3 °C [101 °F]), 
night sweats, or the loss of more than 10 percent of body weight; BM = bone marrow; LDH = lactate dehydroge-
nase; aaIPI = age-adjusted international prognostic index; H-I = high-intermediate. *P < 0.05.
the ABMT group in first complete remission was higher than among 
patients who were kept under monitoring after complete remission. 
The complete remission rate among the GCB-like DLBCL cases 
was 70.8% (CI: 67-74) and among the ABC-like cases, it was 61.2% 
(CI: 59-63) (P = 0.29). The overall survival among GCB-like cases at 
60 months was 46.8% and among ABC-like cases, it was 43.3% (P = 
0.885) (Table 3). The disease-free survival at 60 months was 60.8% 
for the GCB-like subgroup and 55.3% for the ABC-like subgroup (P 
= 0.365). Bcl-2 expression was shown in 27 patients (37%), and only 
14 (51.8%) of them (CI: 48-55) achieved complete remission, while 33 
(72%) (CI: 69-73) of Bcl-2 negative cases achieved complete remission 
(P = 0.073). Bcl-2 positive cases showed overall survival at 60 months of 
16.4% (CI: 17-51.4), while Bcl-2 negative cases showed overall survival 
of 58.1% (CI: 71-119) (P = 0.004) (Table 3). The disease-free surviv-
al for Bcl-2 positive cases was 34% and for Bcl-2 negative cases, it was 
65.6% (P = 0.12) (Table 3).
Multivariate analysis 
In multivariate analysis, Bcl-2 positive cases showed a poor prog-
nosis for overall survival (P = 0.01) with a relative risk (RR) of 2.44 
(CI: 1.2-4.8). Likewise, the primary therapeutic response was poor (P < 
0.0001), with RR of 7.36 (CI: 3.5-15.1). After excluding the primary 
response variable from the analysis, Bcl-2 expression remained an in-
dependent prognostic factor for survival (P = 0.006) with RR of 2.49 
(CI: 1.3-4.7).
dISCUSSIOn
Previous studies have identified two molecularly distinct subtypes 
of DLBCL that are indicative of different functional stages of B-cell 
differentiation.4,14 One type expresses the gene characteristics of GCB-
like cells (GCB-like DLBCL), whereas the other type expresses genes 
that are normally seen during in vitro activation of peripheral blood B-
cells (ABC-like DLBCL). Different prognoses for these two subgroups 
have been demonstrated, regardless of the IPI risk.6,8,11,15 More recent-
ly, Hans et al. have demonstrated similar results using immunohis-
tochemical profiling, for other markers such as CD10, Bcl-6 and IRF4 
(MUM1).11 Contrary to these studies, which evaluated patients with 
mixed IPI risk, we evaluated cases restricted to high-risk DLBCL that 
did not show survival differences between the GCB-like and ABC-like 
subgroups. Similarly, Nyman et al. demonstrated that this division does 
not have prognostic value when patients are treated with CHOP and 
the monoclonal antibody anti-CD20 (rituximab) (CHOP-R).15 These 
results show that prognostic factors change according to treatment, and 
according to the type of subgroups analyzed. They also show the hetero-
geneity of this disease.
On the other hand, there has not been any consensus regarding the 
prognostic value of CD10 antigen expression in DLBCL cases. Some 
authors have correlated it with better prognosis9 and others with worse 
prognosis. We did not show any correlation between CD10 expression 
and the likelihood of remission or survival, among high-risk DLBCL 
cases. Similarly, Bcl-6 antigen has been associated with good progno-
sis among patients treated with CHOP-like regimens, but not with 
CHOP-R16 or with sequential chemotherapy followed by ABMT in 
high-risk DLBCL cases.17
MUM1 (IRF4) has been demonstrated in post-GCB-like cases, and 
it is associated with ABC-like DLBCL and with worse prognosis. This 
subgroup of DLBCL has been associated with immunoblastic-like mor-
phology and extranodal disease.1 In our report, 53.4% patients were 
positive for MUM1 expression, similar to the findings of Colomo.18 A 
study on high-risk patients who underwent sequential chemotherapy 
followed by ABMT showed that cutoff values lower than 70% positive 
expression of MUM1 cells did not have an impact on overall survival. 
On the other hand, when cutoff values higher than 70% positive expres-
sion of MUM1 were considered, favorable overall survival was observed 
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for MUM1-negative cases.17  In the present study, we used a cutoff value 
of 10%, which may explain the lack of prognostic value for this marker 
in our study. The result from van Imhoff et al. suggests that the cutoff 
points for these markers should be determined according to their clini-
cal significance for clinical application.
Iqbal et al. have suggested that the significance of Bcl-2 should be 
assessed within the context of DLBCL subgroups because of the con-
troversy surrounding its prognostic significance.14 Some authors have 
correlated Bcl-2 expression with high-risk DLBCL.17 In our report, we 
observed Bcl-2 expression in 37% of our patients with high-risk DLB-
CL and we did not demonstrate any prognostic significance regarding 
the remission rate, even though the P-value was close to statistical sig-
nificance (P = 0.07). However, there was prognostic significance with 
regard to overall survival (P = 0.004), as also reported by some other 
authors with similar cases.19 In multivariate analyses, Bcl-2 was shown 
to be an independent prognostic factor for survival (P = 0.01 and RR = 
2.44), and these patients might benefit from protocols with greater ag-
gressiveness, using rituximab-based chemotherapy.20,21
Our study is limited by its retrospective design with a small num-
ber of patients. Therefore, prospective studies with a larger number of 
patients are needed in order to evaluate the role of this protein in high-
intermediate and high risk DLBCL cases among our population. 
COnClUSIOn
Bcl-2 protein was expressed in 37% of the high-risk DLBCL cases, 
with no difference between the ABC-like DLBCL and GCB-like DL-
BCL subgroups. Bcl-2 expression was associated with worse overall sur-
vival among high-risk DLBCL cases.  
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